We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tiens Biotech Grp. (Usa) Common Stock | AMEX:TBV | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
OMB
APPROVAL
|
|
OMB
Number: 3235-0058
Expires:
May 31, 2012
Estimated
average burden
hours
per response2.50
|
||
FORM
12b-25
|
||
SEC
FILE NUMBER
|
||
001
32477
|
||
CUSIP
NUMBER
|
||
(Check
One)
:
|
¨
Form
10-K
¨
Form
20-F
¨
Form
11-K
x
Form
10-Q
¨
Form
N-SAR
¨
Form
N-CSR
|
88650T104
|
For
Period Ended:
June 30,
2010
|
|||
o
|
Transition
Report on Form 10-K
|
||
o
|
Transition
Report on Form 20-F
|
||
o
|
Transition
Report on Form 11-K
|
||
o
|
Transition
Report on Form 10-Q
|
||
o
|
Transition
Report on Form N-SAR
|
||
For
the Transition Period Ended:
_____________________________
|
Read
attached instruction sheet before preparing form. Please Print
or Type.
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained
herein.
|
If
the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
|
Full
Name of Registrant
|
Tiens
Biotech Group (USA), Inc.
|
Former
Name if Applicable
|
|
Address
of Principal Executive Office
(Street and
Number)
|
No.
6, Yuanquan Road, Wuqing New-Tech Industrial Park
|
City,
State and Zip Code
|
Tianjin,
PRC 301700
|
x
|
(a)The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
(b)The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due
date; and
(c)The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|||
Mitchell
S. Nussbaum, Esq.
|
212
|
407-4159
|
||
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
||
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months (or for such shorter) period
that the registrant was required to file such reports) been
filed? If answer is no, identify report(s).
|
x
Yes
¨
No
|
||
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
¨
Yes
x
No
|
||
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
|
||||
|
Date:
August 16, 2010
|
By:
|
/s/ Jinyuan Li
Name: Jinyuan
Li
Title: Chief
Executive Officer
|
ATTENTION
|
||
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations
(See 18 U.S.C. 1001).
|
1 Year Tiens Biotech GR Usa Chart |
1 Month Tiens Biotech GR Usa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions